Non-Controlling Interest Treatment in Pre-IPO Group Financials

The Hong Kong Stock Exchange’s (HKEX) 2024–2025 annual review of listing applications revealed a recurring deficiency in the treatment of non-controlling interests (NCI) within pre-IPO group financials, a trend that has intensified as more Mainland Chinese conglomerates with complex subsidiary structures seek listings on the Main Board. According to the HKEX’s Listing Decision LD143-2024 (October 2024), 23% of rejected or deferred applications in the technology and consumer sectors cited inadequate disclosure or misapplication of HKFRS 10 Consolidated Financial Statements and HKAS 27 Separate Financial Statements regarding NCI. This regulatory scrutiny is not merely a compliance checkbox; it directly impacts the valuation of the group, the structure of the placing, and the sponsor’s liability under the SFC’s Code of Conduct (Chapter 17, paragraph 17.6). For a CFO preparing a prospectus for a group with partially-owned subsidiaries—common in PRC-based tech groups with BVI or Cayman intermediate holding companies—the distinction between a controlling and non-controlling interest in the pre-IPO period can determine whether the HKEX accepts the group’s historical financial statements as a reliable basis for pricing. The 2025 HKEX Guidance Letter HKEX-GL112-25 (effective 1 January 2025) further tightened requirements, mandating that any change in NCI during the track-record period must be explained in the accountants’ report as a “significant transaction” under Listing Rule 4.04. This article dissects the specific regulatory requirements, common pitfalls in pre-IPO group structures, and the accounting mechanics that listing applicants must master to avoid a “further information” letter from the Listing Division.

The Regulatory Framework for NCI in Pre-IPO Financials

The HKEX’s Listing Rules, specifically Chapter 4 (Accountants’ Reports and Pro Forma Financial Information), require that the accountants’ report for a listing applicant present a true and fair view of the group’s financial position for the three full financial years (or two for GEM) immediately preceding the listing. When a group includes subsidiaries in which the parent does not hold 100% equity, the treatment of NCI becomes a focal point for both the HKEX and the SFC. The core principle, as articulated in HKEX Guidance Letter GL56-13 (updated March 2023), is that the group’s consolidated financial statements must clearly distinguish between equity attributable to owners of the parent and equity attributable to NCI. Any misclassification can lead to a restatement of the track record, which the HKEX views as a material deficiency under Listing Rule 9.03(3).

HKFRS 10 and the Definition of Control

The first hurdle for any pre-IPO group is establishing which entities are subsidiaries and, therefore, where NCI arises. HKFRS 10 defines control as having power over the investee, exposure or rights to variable returns from the investee, and the ability to use power to affect those returns. In a pre-IPO context, this is often tested when a group has a joint venture (JV) or an associate that is structured through a BVI or Cayman vehicle with a minority partner. For example, if a PRC operating subsidiary is 60% owned by the listing applicant and 40% by a third-party investor, the 40% is NCI. However, if the 40% holder has substantive participating rights—such as veto power over key operating decisions under the JV agreement—the HKEX may reclassify the entity as a joint arrangement under HKFRS 11, eliminating NCI entirely. The Listing Decision LD143-2024 specifically cited a case where an applicant treated a 35% minority interest as NCI, but the minority’s contractual right to appoint two of five board members meant the applicant did not have control. The HKEX required the financials to be restated, delaying the listing by four months.

HKAS 27: Separate Financial Statements and the Parent’s Standalone Position

While the consolidated financial statements are the primary focus for the HKEX’s review of track record, the parent’s separate financial statements—usually prepared under HKAS 27—are also scrutinised, particularly for the purpose of the sponsor’s due diligence under the SFC’s Code of Conduct paragraph 17.6. In the parent’s separate accounts, investments in subsidiaries are typically carried at cost or fair value. Any dividend received from a subsidiary that is funded by the subsidiary’s retained earnings—including earnings attributable to NCI—must be disclosed. The HKEX Guidance Letter GL38-12 (updated June 2022) notes that if a subsidiary pays a dividend out of profits that include NCI’s share, the parent must ensure that the NCI’s consent is obtained and that the dividend does not breach the subsidiary’s constitutive documents or PRC company law. Failure to document this consent has been a common reason for “further information” requests in 2024, with the HKEX asking for board minutes or shareholder resolutions from the BVI or Cayman subsidiary level.

Structuring NCI in the Pre-IPO Period

The pre-IPO period—typically the three years before the listing application—is when most groups reorganise their shareholding structures to optimise for the IPO. This reorganisation often involves the acquisition or disposal of NCI, which triggers specific accounting and disclosure requirements under HKFRS 3 Business Combinations and HKAS 27.

Acquisitions of NCI: Equity Transactions or Business Combinations?

A common pre-IPO move is for the listing applicant to acquire the remaining NCI in a key subsidiary to simplify the group structure for investors. Under HKFRS 10, an acquisition of NCI after control is obtained is accounted for as an equity transaction—no goodwill or gain on bargain purchase is recognised. The difference between the consideration paid and the carrying amount of the NCI acquired is recognised directly in equity (attributable to owners of the parent). For example, if the listing applicant pays HKD 50 million to acquire a 20% NCI in a subsidiary with a net asset value of HKD 200 million (so NCI carrying amount of HKD 40 million), the HKD 10 million excess is debited to retained earnings. The HKEX Guidance Letter GL112-25 (2025) now requires that any such acquisition during the track-record period be disclosed in the prospectus as a “related party transaction” if the NCI seller is connected to the applicant—a common scenario when the NCI is held by a founder’s family trust. The sponsor must confirm that the consideration was determined on an arm’s length basis, with a valuation report from an independent valuer (HKIS or RICS qualified) attached to the sponsor’s due diligence file.

Disposals of NCI: Loss of Control and Deconsolidation

When a group disposes of a subsidiary or reduces its stake such that control is lost, the accounting treatment shifts. Under HKFRS 10, if the listing applicant loses control of a subsidiary, it must derecognise the subsidiary’s assets, liabilities, and NCI, and recognise any resulting gain or loss in profit or loss. The remaining interest (if any) is remeasured at fair value. This is a high-risk area for pre-IPO groups because the gain or loss can be material and can distort the track-record earnings. The HKEX Listing Decision LD127-2023 (December 2023) involved an applicant that sold a 51% subsidiary (retaining 49%) during the track-record period, recognising a gain of HKD 120 million. The HKEX questioned whether the sale was a “disposal of a substantial subsidiary” under Listing Rule 4.05, which requires a separate pro forma financial statement. The applicant had to restate its accountants’ report to show the gain as an exceptional item, with full disclosure of the fair value of the retained 49% interest. The SFC’s Code of Conduct paragraph 17.6(d) requires the sponsor to verify that the fair value was determined using a recognised valuation methodology (e.g., discounted cash flow or market approach) and that the valuation was not influenced by the pre-IPO pricing.

NCI in VIE Structures

For PRC-based groups using Variable Interest Entity (VIE) structures—common in the technology and education sectors—the treatment of NCI is particularly complex. Under HKFRS 10, a VIE is consolidated if the listing applicant has power over the VIE, exposure to variable returns, and the ability to use power to affect those returns. The NCI in a VIE is typically held by the PRC nominee shareholders (often the founder or management team). The HKEX Guidance Letter GL94-18 (updated November 2024) explicitly states that the NCI in a VIE must be presented in the consolidated financial statements, and the contractual arrangements (e.g., exclusive call options, voting rights agreements) must be disclosed in the prospectus. A 2024 review by the HKEX of 15 VIE-structure applicants found that 7 had incorrectly classified the nominee shareholders’ equity as a liability rather than NCI, based on the PRC nominee’s substantive rights under the VIE agreements. The correct treatment, per HKFRS 10, is to classify it as NCI unless the nominee has no exposure to the VIE’s residual returns—a rare scenario. The sponsor must obtain a legal opinion from PRC counsel (qualified to issue opinions on the PRC Foreign Investment Law 2020) confirming that the VIE agreements do not give the nominee substantive liquidation rights.

Disclosure Requirements in the Prospectus

The prospectus is the primary document through which the HKEX and potential investors assess the group’s financial health. The disclosure of NCI must be precise, with clear breakdowns and sensitivity analyses.

The Accountants’ Report and Notes

The accountants’ report, prepared under HKFRS and reviewed by the HKEX under Listing Rule 4.04, must include a note on NCI that shows the movement in NCI over the track-record period. This includes:

• The opening balance of NCI.
• The share of profit or loss attributable to NCI.
• Other comprehensive income attributable to NCI.
• Dividends paid to NCI.
• Acquisitions or disposals of NCI.
• The closing balance.

The HKEX Guidance Letter GL112-25 (2025) now requires that the note also disclose, for each material subsidiary with NCI, the proportion of ownership interest held by NCI, the dividends paid to NCI, and the subsidiary’s total assets, liabilities, revenue, and profit or loss. For example, if a group has three subsidiaries with NCI of 30%, 25%, and 20%, the prospectus must show each subsidiary’s contribution to group revenue (e.g., Subsidiary A: HKD 150 million, Subsidiary B: HKD 80 million, Subsidiary C: HKD 45 million) and the NCI’s share of profit (e.g., HKD 4.5 million, HKD 2.0 million, HKD 0.9 million). This level of granularity is intended to allow investors to assess the risk that NCI may block future dividends or strategic decisions.

Pro Forma Financial Information

Under Listing Rule 4.29, the prospectus must include pro forma financial information that illustrates the effect of the listing on the group’s net assets and earnings per share. When NCI is present, the pro forma adjustments must show the impact of any changes in NCI that are expected to occur after the listing, such as the exercise of a put option held by a minority shareholder. The HKEX Guidance Letter GL55-13 (updated March 2023) requires that the pro forma be prepared on a basis consistent with the historical financial statements and that the assumptions be clearly stated. For instance, if the listing applicant has a put option from an NCI holder that allows the holder to sell its 20% stake to the applicant at a price based on the IPO valuation, the pro forma must show the potential reduction in equity (the consideration paid) and the increase in the parent’s ownership. The sponsor must confirm that the put option is a financial liability under HKAS 32, and the pro forma must reflect the liability’s impact on net current assets.

Risk Factors and NCI

The prospectus risk factors section must address the specific risks associated with NCI. The SFC’s Code of Conduct paragraph 17.6(e) requires the sponsor to ensure that the risk factors are “specific and not generic.” For NCI, common risks include:

• The NCI holder’s ability to block strategic decisions (e.g., asset sales, mergers) under the subsidiary’s constitutive documents.
• The potential for dividend leakage, where the subsidiary pays dividends to NCI that reduce the group’s available cash for the listing applicant.
• The risk of a “deadlock” if the NCI holder has veto rights under a shareholders’ agreement.

A 2024 enforcement case by the SFC (SFC v. Sponsor A, unreported, 2024) involved a sponsor that failed to disclose that a 40% NCI holder in a PRC subsidiary had a contractual right to block the subsidiary’s IPO—a right that was exercised after the listing, causing the subsidiary to be deconsolidated. The sponsor was fined HKD 15 million and the sponsor’s Responsible Officer was suspended for 18 months. This case underscores the importance of a thorough review of all JV and shareholders’ agreements.

Practical Implications for the Sponsor and CFO

The treatment of NCI in pre-IPO financials is not just an accounting exercise; it has direct implications for the listing timeline, the valuation of the group, and the liability of the sponsor.

Valuation and Pricing

The HKEX’s Listing Rules do not prescribe a specific valuation methodology for NCI, but the sponsor must ensure that the IPO price (the offer price per share) is consistent with the group’s valuation as presented in the accountants’ report. If the group has significant NCI, the market capitalisation implied by the IPO price will be compared to the equity attributable to owners of the parent. For example, if the group’s consolidated net assets are HKD 1 billion, with HKD 200 million attributable to NCI, and the IPO price implies a market capitalisation of HKD 1.5 billion, the sponsor must justify why the NCI is valued at only 13.3% of the group’s market cap (HKD 200 million / HKD 1.5 billion). The HKEX may ask for a valuation report that shows the fair value of the NCI, typically using a discounted cash flow or market multiple approach. The valuation must be consistent with the methodology used in the accountants’ report for impairment testing under HKAS 36.

Sponsor Due Diligence

The SFC’s Code of Conduct paragraph 17.6 requires the sponsor to conduct “reasonable due diligence” on all material aspects of the listing applicant, including the treatment of NCI. The sponsor’s due diligence must include:

• Review of all constitutive documents of material subsidiaries (e.g., BVI articles of association, Cayman memoranda, PRC joint venture agreements).
• Verification that the NCI holder’s consent has been obtained for any dividends paid during the track-record period.
• Confirmation that the accounting treatment of NCI is consistent with HKFRS and the HKEX’s guidance.
• A legal opinion from qualified counsel in the subsidiary’s jurisdiction confirming that the NCI holder’s rights do not give it control or significant influence.

The HKEX Guidance Letter GL56-13 (2023) notes that the sponsor must document its review of NCI in the due diligence memorandum, with specific reference to the accounting standards and listing rules applied. Failure to do so can result in the HKEX rejecting the listing application or, in severe cases, the SFC taking enforcement action against the sponsor.

Actionable Takeaways for the Pre-IPO Team

1. Audit all subsidiary constitutive documents before the track-record period begins: Obtain and review the BVI, Cayman, or PRC joint venture agreements for any minority veto rights that could reclassify the entity as a joint arrangement under HKFRS 11, eliminating NCI and potentially requiring a restatement of financials.
2. Document every NCI transaction with a valuation report: Any acquisition or disposal of NCI during the three-year track record must be supported by an independent valuer’s report (HKIS or RICS qualified) to confirm arm’s length pricing, as required by HKEX Guidance Letter GL112-25 (2025).
3. Prepare a granular NCI note in the accountants’ report: Disclose each material subsidiary’s NCI percentage, revenue, profit, and dividends separately, in line with HKEX Guidance Letter GL112-25, to avoid a “further information” letter from the Listing Division.
4. Stress-test the pro forma for NCI-related put options: Model the impact of any put or call options held by NCI holders on the group’s net assets and earnings per share, and ensure the pro forma adjustments are clearly stated under Listing Rule 4.29.
5. Engage PRC counsel early for VIE structures: Obtain a legal opinion confirming that the VIE nominee shareholders’ equity is correctly classified as NCI under HKFRS 10, not as a liability, and that the nominee has no substantive liquidation rights under the PRC Foreign Investment Law 2020.